Skip to main content

Advertisement

SpringerLink
Log in

Killing two kinase families with one stone

  • News & Views
  • Published:

From Nature Chemical Biology

View current issue Submit your manuscript

Multitargeted protein kinase inhibitors have shown great promise in cancer therapy, but the selectivity profiles of these compounds have largely relied on serendipity or 'off-target' activities rather than rational drug design. Purposefully designed compounds with activity against multiple target kinases bring us a step closer to personalized medicine.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Size and shape selectivity of dual PI3K and tyrosine kinase inhibitors.

References

  1. Manning, G., Whyte, D.B., Martinez, R., Hunter, T. & Sudarsanam, S. Science 298, 1912–1934 (2002).

    Article  CAS  Google Scholar 

  2. Knight, Z.A. & Shokat, K.M. Chem. Biol. 12, 621–637 (2005).

    Article  CAS  Google Scholar 

  3. Bain, J. et al. Biochem. J. 408, 297–315 (2007).

    Article  CAS  Google Scholar 

  4. Apsel, B. et al. Nat. Chem. Biol. 4, 691–699 (2008).

    Article  CAS  Google Scholar 

  5. Sebolt-Leopold, J.S. & English, J.M. Nature 441, 457–462 (2006).

    Article  CAS  Google Scholar 

  6. Petrelli, A. & Giordano, S. Curr. Med. Chem. 15, 422–432 (2008).

    Article  CAS  Google Scholar 

  7. Quintas-Cardama, A., Kantarjian, H. & Cortes, J. Nat. Rev. Drug Discov. 6, 834–848 (2007).

    Article  CAS  Google Scholar 

  8. Marone, R., Cmiljanovic, V., Giese, B. & Wymann, M.P. Biochim. Biophys. Acta 1784, 159–185 (2008).

    Article  CAS  Google Scholar 

  9. Hayakawa, M. et al. Bioorg. Med. Chem. Lett. 17, 2438–2442 (2007).

    Article  CAS  Google Scholar 

  10. Fan, Q.W. et al. Cancer Cell 9, 341–349 (2006).

    Article  CAS  Google Scholar 

  11. Raynaud, F.I. et al. Cancer Res. 67, 5840–5850 (2007).

    Article  CAS  Google Scholar 

  12. Maira, S.M. et al. Mol. Cancer Ther. 7, 1851–1863 (2008).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Benoit Bilanges and Bart Vanhaesebroeck are in the Centre for Cell Signalling, Institute of Cancer, Barts and The London School of Medicine & Dentistry, Charterhouse Square, London EC1M 6BQ, UK. bart.vanh@qmul.ac.uk,

    Benoit Bilanges & Bart Vanhaesebroeck

  2. Neil Torbett is at Piramed Pharma, 957 Buckingham Avenue, Slough, Berkshire SL1 4NL, UK.,

    Neil Torbett

Authors
  1. Benoit Bilanges
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Neil Torbett
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bart Vanhaesebroeck
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

B.V. is an advisor to Intellikine, and N.T. is a paid employee of Piramed Pharma.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bilanges, B., Torbett, N. & Vanhaesebroeck, B. Killing two kinase families with one stone. Nat Chem Biol 4, 648–649 (2008). https://doi.org/10.1038/nchembio1108-648

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nchembio1108-648

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation